|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||51.49 - 53.28|
|52-week range||51.18 - 129.79|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||27.11|
|Forward dividend & yield||1.43 (2.76%)|
|Ex-dividend date||28 Sept 2021|
|1y target est||80.00|
The company's blockbuster cancer drug Keytruda was approved in Japan to treat patients with certain types of endometrial cancer.
Regulatory and other pipeline updates from NVAX and BBIO are among a few key highlights from the biotech sector during the past week.
Image source: The Motley Fool. Biogen inc (NASDAQ: BIIB)Q3 2021 Earnings CallOct 20, 2021, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning.